Trial Profile
Phase II Study of Heme Arginate in Patients Planned for Cardiac Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Haem arginate (Primary)
- Indications Acute kidney injury
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms HACS
- 09 Dec 2015 Status changed from recruiting to completed according to United Kingdom Clinical Research Network record.
- 27 Nov 2015 Accrual to date is 105% according to United Kingdom Clinical Research Network record.
- 27 Aug 2015 Accrual to date is 15% according to United Kingdom Clinical Research Network record.